Peptides for recovery: what evidence exists?
What the evidence really says about BPC-157, thymosin beta-4, CJC-1295, and ipamorelin for injury recovery.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
The quick overview
“Recovery” can mean tendon healing, wound repair, pain, return to activity, sleep, or muscle repair. A study measuring cells, rodents, or a hormone level may not answer any of those human questions.
BPC-157 and thymosin beta-4 are supported mainly by preclinical research for broad recovery claims. CJC-1295 and ipamorelin have limited human pharmacology data but no FDA-approved recovery use.
Side-by-side comparison
| Peptide | Status | Evidence | Studied for |
|---|---|---|---|
| BPC-157 | Not FDA approved | Mostly animal or lab research | Tissue repair in animal models; Gastrointestinal effects in animal models; Inflammation and blood-vessel signaling in preclinical research |
| Thymosin beta-4 | Not FDA approved | Mostly animal or lab research | Tissue and wound repair; Corneal healing; Cardiac repair |
| CJC-1295 | Not FDA approved | Early human evidence | Growth hormone and IGF-1 levels; Pharmacology and tolerability |
| Ipamorelin | Not FDA approved | Early human evidence | Growth hormone release; Gastrointestinal motility; Postoperative ileus |
Studied for
Tissue repair in animal models · Gastrointestinal effects in animal models · Inflammation and blood-vessel signaling in preclinical research
Studied for
Tissue and wound repair · Corneal healing · Cardiac repair
Studied for
Growth hormone and IGF-1 levels · Pharmacology and tolerability
Studied for
Growth hormone release · Gastrointestinal motility · Postoperative ileus
Approved versus investigational
An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.
What researchers are studying
- Tissue-repair pathways in animal and laboratory models
- Wound and corneal healing research
- Growth-hormone signaling
- Inflammation and cell migration
Risks and reasons for caution
- Animal healing signals do not prove faster or safer recovery in humans.
- FDA has described evidence gaps and potential safety risks for these substances in compounding contexts.
- Injury pain can signal a condition that needs diagnosis; masking or delaying care can create harm.
What remains uncertain
- Whether claimed effects translate to meaningful human recovery
- Long-term safety, interactions, and uncommon adverse effects
- Whether online products contain the claimed identity and strength
Questions to ask a healthcare professional
1. What is the diagnosis, and what is the usual recovery timeline?
2. Is the evidence from people with this injury or only from models?
3. What proven rehabilitation or treatment options exist?
4. Could this delay appropriate imaging, rehabilitation, or medical care?
Plain-English takeaway
For popular recovery peptides, scientific interest is real but clinical certainty is not. The strongest claims are often built on the weakest leap: from laboratory or animal results to promised human recovery.
References
- 1FDA: understanding the risks of compounded drugs
FDA overview of how compounded drugs differ from FDA-approved drugs.
- 2ClinicalTrials.gov
U.S. National Library of Medicine registry of clinical studies.
- 3PubMed
Peer-reviewed biomedical literature indexed by the National Library of Medicine.